Equities

Cementos Bio Bio SA

CEMENTOS:SGO

Cementos Bio Bio SA

Actions
IndustrialsConstruction and Materials
  • Price (CLP)675.00
  • Today's Change-27.00 / -3.85%
  • Shares traded310.00
  • 1 Year change--
  • Beta0.1191
Data delayed at least 20 minutes, as of Apr 12 2024 17:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cementos Bio Bio SA is a Chile-based company primarily engaged in the construction materials industry. The Company’s main businesses are structured in two areas: Cement and Ceramics. The Cement area comprises the production, distribution and sale of cement, lime, concrete, mortar and aggregates. In the Ceramics area, the Company is active in the production, distribution and sale of bathroom fixtures, such as bathtubs, faucets, fittings and plastic accessories, among others. As of December 31, 2012, the Company owned such subsidiaries as Industria Nacional de Cemento SA, Cementos Bio Bio Centro SA, Ready Mix SA, Inversiones San Juan SA, Minera Rio Colorado SA, Inversiones Cementos Bio Bio SA, Morteros y Aridos Dry Mix Ltda and Inacal SA, among others. The Company’s major shareholder was Inversiones y Desarrollos Ltda was its major shareholder with 26.42% of its interest.

  • Revenue in CLP (TTM)348.98bn
  • Net income in CLP22.80bn
  • Incorporated1958
  • Employees1.14k
  • Location
    Cementos Bio Bio SAAvenida Andres Bello 245718th Floor, Costanera Center BuildingPROVIDENCIA 7500521ChileCHL
  • Phone+56 225607000
  • Fax+56 225607051
  • Websitehttps://biobiocementos.cl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Melon SA241.82bn485.82m100.60bn568.00206.900.51294.580.4160.00170.00170.86530.70190.63424.596.34--0.12740.07620.1740.097330.5329.420.20090.12670.37780.53360.347---1.284.79105.03-44.30-18.35--
Compania Industrial El Volcan S.A.151.26bn18.98bn182.25bn590.009.600.68936.021.20253.12253.122,016.853,525.290.39713.047.33256,379,400.004.989.535.3810.5331.4938.2112.5519.981.98--0.220731.79-13.936.14-42.952.629.54-10.32
Cementos Bio Bio S.A.348.98bn22.80bn185.48bn1.14k8.140.72563.740.531586.2886.281,320.81967.510.72173.796.65305,590,500.004.723.765.904.5137.1336.346.545.900.89652.760.324372.804.495.86115.882.892.44-15.20
Cemento Polpaico S.A.341.14bn-4.72bn205.20bn1.61k--1.6416.160.6015-185.05-185.0513,366.194,899.330.88643.966.58212,281,300.00-1.230.5091-1.900.724729.1731.21-1.380.53690.5422-0.23430.5587---7.4015.42-220.45--12.62--
Data as of Apr 12 2024. Currency figures normalised to Cementos Bio Bio SA's reporting currency: Chilean Peso CLP

Institutional shareholders

0.48%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 28 Mar 20241.22m0.46%
Dimensional Fund Advisors Ltd.as of 29 Feb 202455.35k0.02%
DFA Australia Ltd.as of 31 Mar 20241.96k0.00%
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.